Figure 3
From: IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis
EndoS treatment does not limit T cell activation, B cell activation, or CNS recruitment of lymphoid or myeloid cells. (A) EndoS has no impact on peripheral T cell priming or recall responses of spleen cells in response to MOG35-55 peptide, as measured using a 3 H-thymidine incorporation assay. EndoS treatment does not influence the (B) peripheral frequency or activation or (C) CNS (spinal cord) infiltration of important lymphoid and myeloid immune cell populations, as measured (mean ± s.e.m.) by flow cytometry analysis of cells isolated from EndoS-treated mice (n = 6) and PBS-treated mice (n = 4) at day 25 post-immunization. (D) CpG is equally effective in stimulating the proliferation of splenic B cells from PBS- or EndoS-treated mice, as determined by 3 H-thymidine incorporation after 3 days of culture. (E) EndoS treatment does not affect the frequency or activation status of immune cells in the bone marrow.